Feverfew (Tanacetum parthenium)

Tier 3 — weak evidence · Migraine prevention · Inflammation

A traditional herb for migraine prevention, but evidence is weak. A 2024 Cochrane review found only weak evidence that feverfew reduces migraine frequency when taken daily. Results are inconsistent across trials. Can cause mouth ulcers and rebound headaches if stopped abruptly. Taper gradually when discontinuing. Riboflavin is a better-supported option.

Dose: 50–100 mg/day standardised to 0.2% parthenolide; taper gradually to avoid rebound